1. Introduction {#sec1}
===============

Obstructive sleep apnea (OSA), a common disorder, is often asymptomatic, and the prevalence of patients with OSA, who do not present clinical syndrome, might be as high as 20--30% in the middle-aged population \[[@B1]\]. OSA is a significant source of morbidity and mortality \[[@B2]\]. OSA is characterized by recurrent episodes of upper airway collapses during sleep. These recurrent episodes of upper airway collapse usually are accompanied by oxyhemoglobin desaturation and terminated by brief arousals which result in marked sleep fragmentation and chronic excessive daytime sleepiness (EDS) \[[@B1], [@B3]\]. As a result, there are an increased expression of systemic inflammatory markers, a sustained activation of the sympathetic nervous system \[[@B4]\], and derangement in endothelial function \[[@B5]\]. Many of these physiologic and biochemical abnormalities are implicated in the pathogenesis of cardiovascular and cerebrovascular diseases.

Carotid intima media thickness (CIMT) is a surrogate marker for atherosclerotic disease and a means to detect subclinical atherosclerosis \[[@B6]\]. CIMT as measured by B-mode ultrasound represents the combined thickness of the intimal and medial layers of the carotid artery. Despite its limitations, measurement of CIMT is a noninvasive technique and has several advantages over other surrogate markers of atherosclerotic disease.

CIMT can be recorded multiple times without inflicting any physical harm \[[@B7]\]. Patients can also have repeated CIMT measurements done without being exposed to radiation, which is commonly associated with other arterial visualization methods \[[@B8]\]. Lastly, measurement of CIMT uses equipment that is readily available, relatively inexpensive, and not hindered by patient anatomy \[[@B9]\].

Multiple studies have shown that increased CIMT is a valid predictor of the probability of future cardiovascular events and can predict the presence of coronary artery disease (CAD) \[[@B10], [@B11]\]. OSA is thought to be associated in the pathogenesis of CAD along with other cerebrovascular events. OSA patients are at increased risk of cardiovascular morbidity and mortality, mostly involving systemic hypertension, coronary heart disease, stroke, and heart failure \[[@B12]\]. Oxidative stress, low grade inflammation, and sympathetic activation have been proposed as key mechanisms explaining the increased cardiovascular risk in OSA. Repetitive desaturation-reoxygenation sequences have been shown to generate reactive oxygen species (ROS), impair serum antioxidant capacity, and enhance lipid peroxidation \[[@B13]\]. This oxidative stress is known to damage the vascular endothelium, to promote atherosclerosis, and ultimately to favor the later occurrence of adverse cardiovascular events \[[@B13]\]. Therefore, a direct correlation between OSA and elevated CIMT may be elucidated \[[@B14]\]. However, studies evaluating this relationship have been small and have yielded conflicting results. Therefore, a meta-analysis was performed to assess if there is any direct correlation between OSA and CIMT.

2. Methods {#sec2}
==========

We performed this review in accordance with PRISMA guidelines for performing meta-analysis. A protocol was prospectively developed, detailing the objectives, criteria for study selection, and approach to assessing the study quality, primary outcome, and methodology.

2.1. Data Source and Study Selection {#sec2.1}
------------------------------------

Studies for review were found searching the PubMed, Cochrane, and EMBASE databases from January 01, 1960 to December 31, 2012. Unpublished data from scientific meetings were not searched since most abstracts do not provide detail data needed for meta-analysis. The searches were conducted using the following keywords: sleep apnea, obstructive sleep apnea, carotid disease, intima media thickness, and carotid atherosclerosis. Abbreviated forms of keywords were also searched to ensure that any relevant sources were not excluded. Multiple authors individually searched for and scored manuscripts for inclusion. Manuscripts were scored in duplicates, and if manuscripts were scored differently by two authors, they were reviewed by a third author to finalize inclusion.

2.2. Studies and Endpoint Definitions {#sec2.2}
-------------------------------------

CIMT was selected as a marker for atherosclerotic process associated with OSA based on review of literature. Inclusion criteria defined for study selection were as follows: (1) the study had to be in English; (2) full text manuscripts had to be available; (3) the study had to contain values corresponding to CIMT recorded by ultrasound; (4) the study had to include at least two separate groups with one being subjects diagnosed with obstructive sleep apnea and the other group consisting of subjects without obstructive sleep apnea; (5) OSA was strictly defined as AHI ≥5/h; (6) the study must have reported values in mean and standard deviation or median with 95% confidence interval; (7) subject number for all groups had to be reported; (8) the study must have been performed on adult humans. Studies that did not meet the above criteria were excluded.

2.3. Data Extraction and Statistical Analysis {#sec2.3}
---------------------------------------------

Data was extracted at a study level by a single author and then reviewed by a second author to ensure that no errors were made. CIMT measurements were extracted from studies as mean with standard deviation. Studies with data reported as median with range, mean and standard deviation were calculated utilizing methods outlined by Hozo et al. \[[@B15]\].

Target variable (carotid intima media thickness) was recorded as well as reported demographics (age, gender, and BMI) and confounding factors (AHI, LDL cholesterol, HDL cholesterol, and blood pressure) to evaluate the effect of these parameters on the target by employing subgroup analysis or metaregression.

For studies in which OSA groups were divided based on severity, each set of data was included into the meta-analysis as separate studies. For example, Drager and colleagues \[[@B16]\] divided the OSA subjects into mild, moderate, and severe groups. Therefore, three different sets of data were collected from the study comparing each OSA group to the control. Also, studies in which the additive effects of OSA and another disease process, that is, HTN, metabolic syndrome (MetS) on CIMT, were evaluated; both sets of data were included separately into the meta-analysis. For example, Drager and colleagues \[[@B17], [@B18]\] measured CIMT on patients diagnosed with hypertension and without hypertension with and without OSA. Similarly, Monneret and colleagues \[[@B19]\] measured CIMT on patients diagnosed with metabolic syndrome, with and without OSA.

Risk for bias was assessed at study level, and, at outcome level and according to our inclusion criteria, multiple studies were excluded from the meta-analysis based on OSA diagnosis designation, as these studies used different cutoff values for AHI to define OSA patients, and some studies did not directly classify their subjects as suffering from OSA. For example, Wattanakit and colleagues \[[@B20]\] as well as Sackett and colleagues \[[@B21]\] divided their subjects into groups with or without sleep disordered breathing, with no reference to OSA. Study selection, data extraction, and statistical analyses were all done in accordance with previously published methodology for meta-analyses. Measurement units of carotid intima media thickness used in the meta-analysis were micrometers (*μ*m). If any of the measurements were not reported in the same standard measurement unit that we used, the value was converted to the micrometers.

2.4. Statistical Analysis {#sec2.4}
-------------------------

The statistical analysis was performed by the Comprehensive Meta-Analysis software package (version CM 2.2, Biostat, Englewood, NJ, USA). Heterogeneity analysis by the Cochran\'s *Q* statistics for individual end points across all studies was performed. An *I* ^2^ of 25--49% was considered to represent a low level of heterogeneity, 50--74% a moderate level and 75--100% a high level. A two-sided alpha error of less than 0.05 was considered to be statistically significant.

3. Results {#sec3}
==========

3.1. Literature Search {#sec3.1}
----------------------

The literature was ranked according to the Sackett et al\'s \[[@B22]\] hierarchy of evidence. A total of 95 studies were reviewed for inclusion, and 79 manuscripts were excluded (reviews = 24, case report = 4, expert opinion = 2, non-human studies = 4, non-English paper = 5, non-adult population = 4, study reported no data as two separate groups (OSA and control) = 10, CIMT measured by technology other than ultrasound = 4, study used OSA definition other than AHI \>5/hour = 4 studies, diagnosis of sleep apnea was not made by sleep study = 4, only graphical display of data available = 2, and only abstract available with no usable data = 12). Sixteen studies were eventually pooled for analysis. Quality of evidence was low (3B-individual case-control study) for the 16 included studies.

3.2. Overview of Study and Patient Characteristics {#sec3.2}
--------------------------------------------------

Studies provided 25 data sets with a total of 1415 patients pooled for meta-analysis. Key studies of CIMT measurement in patients with and without OSA are outlined in [Table 1](#tab1){ref-type="table"}.

3.3. OSA and CIMT {#sec3.3}
-----------------

CIMT standardized difference in means ranged from −0.883 to 8.01. The pooled standardized difference in means was 1.40 (LL 0.996 to UL 1.803, *P* \< 0.0001) ([Figure 1](#fig1){ref-type="fig"}).

3.4. Metaregression to Evaluate the Effect of Confounding Factors {#sec3.4}
-----------------------------------------------------------------

Multiple metaregression analyses were performed to evaluate the effect of age, gender, BMI, AHI, LDL cholesterol, HDL cholesterol, and systolic BP on CIMT when reported in manuscripts. Age (Beta 0.059, *P* = 0.0001), gender (Beta 0.010, *P* = 0.015), AHI (Beta 0.012, *P* = 0.0004), and HDL (Beta −0.04, *P* = 0.0004) were found to have modest but significant effect as a confounding factor ([Table 2](#tab2){ref-type="table"}) (Figures [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}, [4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, [7](#fig7){ref-type="fig"}, and [8](#fig8){ref-type="fig"}).

4. Discussion {#sec4}
=============

The existence of vascular inflammation in patients diagnosed with OSA has been supported by many studies. Such processes can cause atherosclerosis of vessels and contribute to the development of cardiovascular and cerebrovascular pathologies. Although atherosclerotic disease cannot be reliably detected by traditional risk assessment, CIMT can be used as a surrogate marker for the inflammatory process and allow for identification of subclinical atherosclerosis \[[@B6]\].

This meta-analysis shows that patients diagnosed with OSA display a statistically significant larger CIMT when compared to controls. There are conflicting results for the association between OSA and increased CIMT. The majority of studies reviewed for this analysis have found elevated CIMT in OSA patients when compared to controls and have also shown that overall thickness of the intima media increases with severity of sleep apnea.

In their case-control studies, Lefebvre et al. \[[@B22]\], Meng et al. \[[@B23]\], Minoguchi et al. \[[@B24]\], Schulz et al. \[[@B25]\], Silvestrini et al. \[[@B26]\], Tanriverdi et al. \[[@B13]\], and Yun et al. \[[@B27]\] have demonstrated a direct relationship between increased CIMT and OSA by comparing 2 groups of subjects, 1 group with OSA and a control group. In each of these studies the OSA group of subjects had a significantly larger average CIMT when compared to that of the controls.

A number of other studies have attained results that confirm the correlation between OSA and increased CIMT, while also demonstrating that CIMT values become even larger as the severity of OSA increases. Altin et al. \[[@B28]\] and Kaynak et al. \[[@B29]\] compared their controls to 2 groups of patients, one diagnosed with mild-moderate OSA and the other diagnosed with severe OSA. In both of these studies, it was determined that CIMT increased in the order of control, mild-moderate OSA, and severe OSA. Li and colleagues \[[@B30]\] divided their subjects into four groups and arrived at similar conclusions. The results they obtained determined that CIMT increased in the order of control, mild OSA, moderate OSA, and severe OSA.

The metaregression analysis we performed to evaluate the effect of age, gender, BMI, AHI, LDL cholesterol, HDL cholesterol, and systolic BP on CIMT showed that age, gender, AHI, and HDL were significant as a confounding factor despite the modest effect (Figures [2](#fig2){ref-type="fig"}--[8](#fig8){ref-type="fig"}) ([Table 2](#tab2){ref-type="table"}). This is in agreement with the literature documenting the significance of these confounding factors in determining the CIMT. Güven et al. found that age and BMI were the most important independent determinants of carotid IMT in their study \[[@B31]\]. Howard et al. reported similar results that IMT measurements show a consistent progression with age and greater values among men \[[@B32]\]. Regarding severity of OSA Drager et al. 2005 \[[@B33]\] compared controls to patients diagnosed with mild-moderate OSA, and severe OSA. They reported that CIMT increased in the order of mild-moderate OSA, control, and severe OSA. Although the control group was determined to have a slightly larger CIMT when compared to the mild-moderate OSA group, the researchers determined that the difference in value was not statistically significant and concluded that IMT is correlated with OSA severity \[[@B33]\].

A study performed by Monneret et al. 2010 \[[@B34]\] obtained results with a similar discrepancy as previously mentioned. They compared the same groups as Drager et al. 2005 \[[@B33]\] and found that their controls and mild-moderate OSA patients had equal CIMT, which was less than that of severe OSA patients. These researchers determined that the CIMT values calculated for the controls and mild-moderate OSA group were not statistically significant and that CIMT was positively correlated with AHI \[[@B34]\].

Saletu and colleagues \[[@B35]\] compared CIMT values of their controls to three groups of patients diagnosed with different severities of OSA: mild, moderate, and severe. They determined that CIMT values increased in the order of control, mild OSA, severe OSA, and moderate OSA. The difference in CIMT values for the moderate and severe OSA groups does not appear to be statistically significant. Therefore, this study does not contradict the hypothesis that CIMT values are positively correlated with increasing severity of sleep apnea.

Drager et al. 2010 \[[@B36]\] and Monneret et al. 2012 \[[@B37]\] performed separate studies to compare CIMT values in patients diagnosed with metabolic syndrome (MetS) with and without OSA. The results of both studies determined that CIMT was significantly increased in MetS patients diagnosed with OSA compared to MetS patients without OSA. The researchers in both studies reached the same conclusion that OSA is very common in MetS patients and that it plays an incremental role in the atherosclerotic burden and occurrence of vascular remodeling in this population \[[@B36], [@B37]\]. Data on blood glucose values and prevalence of Met syndrome were only available for insufficient number of studies; therefore, metaregression cannot be performed for this variable. Drager et al. 2009 \[[@B38]\] performed a study to analyze the combined effects of OSA and hypertension on early markers of atherosclerosis. They compared CIMT values for their controls to 2 groups of patients, one with OSA only and the other with OSA and hypertension. They found that CIMT values increased the order of control, OSA, and OSA + HTN. The researchers concluded that, when OSA is associated with HTN, additive effects are seen on markers of carotid atherosclerosis \[[@B38]\]. Data on prevalence of hypertension were only available for insufficient number of studies; therefore, metaregression cannot be performed for this variable.

There are multiple limitations of this meta-analysis that should be emphasized. It is very clear that the available literature relevant to this study is largely low-level evidence. A potential limitation is that we excluded all papers written in languages other than English, which could raise the possibility of publication bias. Also, we included only studies in which CIMT was evaluated by ultrasonography, even though there are other methods available to assess this value.

Other limitations pertain to the methods of individual studies included in this analysis. There was a heterogeneity in the size of sample populations and also in the patient characteristics of the sample populations between studies. It is known that studies with positive results tend to get published while studies with negative results are less likely to be published in general, and since we only included data from published studies in our meta-analysis, we assume publication bias does exist.

Despite the limitations with this meta-analysis, it was reassuring that the majority of analyzed studies determined that OSA subjects display an increase in CIMT when compared to control individuals. Moreover, most of the studies that divided OSA patients into groups based on AHI found that CIMT is positively correlated with the severity of the disease. These results suggest that selection and sampling biases were not likely to be responsible for the observed associations.

In summary, there appears to be evidence indicating increased CIMT in OSA patients when compared to control populations. Some of this effect is attributed to confounding factors as suggested by metaregression. These findings may explain the high occurrence of atherosclerosis contributing to cardiovascular and cerebrovascular pathologies in patients diagnosed with OSA. Future studies are needed to determine the reliability of CIMT as a disease-associated marker for atherosclerosis in OSA patients, to determine the correlation between CIMT and severity of OSA and to determine whether elevated CIMT due to atherosclerosis could be modified by therapeutic interventions for OSA.
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###### 

Included studies assessing CIMT thickness in adult OSA patients versus control.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Study design   Size of study population          Outcome
  ------------------------------------ -------------- --------------------------------- -----------------------------------------------------------------------------------------
  Altin et al. 2005 \[[@B28]\]         Case-control   30 severe OSA\                    IMT values increase in the order of control, mild OSA, and severe OSA\
                                                      20 mild OSA\                      IMT values increase with severity of OSA
                                                      20 control                        

  Güven et al. 2000 \[[@B31]\]         Case-control   15 severe OSA\                    IMT values increase in the order of mild-moderate OSA, control, and severe OSA
                                                      15 mild-moderate OSA\             
                                                      12 control                        

  Drager et al. 2010 \[[@B36]\]        Case-control   25 OSA\                           IMT values increase in the order of control, OSA, OSA + HTN
                                                      27 OSA + HTN\                     
                                                      22 control                        

  Monneret et al. 2010 \[[@B34]\]      Case-control   51 OSA + Metabolic Syndrome\      IMT values were increased in MetS + OSA compared to control
                                                      30 Metabolic Syndrome (control)   

  Kaynak et al. 2003 \[[@B29]\]        Case-control   36 severe OSA\                    IMT values increase in the order of control, mild-moderate OSA, and severe OSA\
                                                      41 mild-moderate OSA\             IMT values increase with severity of OSA
                                                      37 control                        

  Lefebvre et al. 2008 \[[@B22]\]      Case-control   40 OSA\                           IMT values were increased in OSA group compared to control
                                                      20 control                        

  Li et al. 2009 \[[@B30]\]            Case-control   18 severe OSA\                    IMT values increase in the order of control, mild OSA, moderate OSA, and severe OSA\
                                                      18 moderate OSA\                  IMT values increase with severity of OSA
                                                      16 mild OSA\                      
                                                      18 control                        

  Meng et al. 2009 \[[@B23]\]          Case-control   75 OSA\                           IMT values were increased in OSA group compared to control
                                                      48 control                        

  Minoguchi et al. 2005 \[[@B24]\]     Case-control   36 OSA\                           IMT values were increased in OSA group compared to control
                                                      16 control                        

  Howard et al. 1993 \[[@B32]\]        Case-control   12 severe OSA\                    IMT values are equal between control and mild-moderate OSA, and increased in severe OSA
                                                      19 mild-moderate OSA\             
                                                      10 control                        

  Saletu et al. 2008 \[[@B35]\]        Case-control   26 OSA + Metabolic Syndrome\      IMT values were increased in MetS + OSA compared to control
                                                      9 Metabolic Syndrome (control)    

  Drager et al. 2005 \[[@B33]\]        Case-control   51 severe OSA\                    IMT values increase in the order of control, mild OSA, severe OSA, and moderate OSA
                                                      25 moderate OSA\                  
                                                      27 mild OSA\                      
                                                      44 control                        

  Schulz et al. 2005 \[[@B25]\]        Case-control   35 OSA\                           IMT values were increased in OSA group compared to control
                                                      35 control                        

  Silvestrini et al. 2002 \[[@B26]\]   Case-control   23 OSA\                           IMT values were increased in OSA group compared to control
                                                      23 control                        

  Tanriverdi et al. 2006 \[[@B13]\]    Case-control   40 OSA\                           IMT values were increased in OSA group compared to control
                                                      24 control                        

  Yun et al. 2010 \[[@B27]\]           Case-control   82 OSA\                           IMT values were increased in OSA group compared to control
                                                      22 control                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Metaregressions statistics for evaluated confounding factors.

  Confounding factors   Slope   Intercept   *P* value
  --------------------- ------- ----------- -----------
  Age                   0.059   −1.89       0.0001
  Gender                0.010   0.331       0.015
  BMI                   0.016   0.653       0.39
  AHI                   0.012   0.642       0.0004
  LDLc                  0.016   −1.055      0.077
  HDLc                  −0.04   3.319       0.0004
  Systolic BP           0.001   0.971       0.883
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